Avacta Group Plc Overview
Pro stress-test →Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company provides Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies.
Strategic Profile
Pro stress-test →Avacta is a clinical-stage life sciences company with the pre-CISION platform, a proprietary warhead delivery system designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company is testing its flagship AVA6000 chemotherapy drug in clinical trials, which is highly targeted and results in less healthy cells being caught in the crossfire, reducing side effect severity.
Competitive Landscape
Pro stress-test →Avacta develops cancer immunotherapies combining proprietary Affimer biotherapeutics and precision tumor-targeted chemotherapy platforms. Competes with large pharma ADC developers (Pfizer, Genmab, Seattle Genetics) and emerging PDC/AffDC companies through differentiated FAP-targeting mechanism, though faces typical small-cap biotech competition barriers.
Industry Context
Avacta Group Plc operates in Biotechnology / Oncology Therapeutics & Diagnostics.
Key facts
Founded: 2003 · Headquarters: Wetherby, United Kingdom · Market cap: £227.55M